These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 30721255)

  • 1. Correction: Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study.
    PLOS ONE Staff
    PLoS One; 2019; 14(2):e0212144. PubMed ID: 30721255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study.
    Wegermann K; Henao R; Diehl AM; Murphy SK; Abdelmalek MF; Moylan CA
    PLoS One; 2018; 13(9):e0204308. PubMed ID: 30265706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function.
    Zhang L; Han J
    Biochem Biophys Res Commun; 2017 Apr; 486(2):224-231. PubMed ID: 28235484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCAT1 knockdown-mediated suppression of melanoma cell proliferation and migration is associated with reduced oxidative phosphorylation.
    Zhang B; Xu F; Wang K; Liu M; Li J; Zhao Q; Jiang L; Zhang Z; Li Y; Chen H; Zhang J; Tang X; Zhang J
    Am J Cancer Res; 2021; 11(6):2670-2683. PubMed ID: 34249421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.
    Wang ZQ; Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Guillemette C; Gobeil S; Macdonald E; Vanderhyden B; Bachvarov D
    Oncotarget; 2015 Oct; 6(31):31522-43. PubMed ID: 26372729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction: Free Fatty Acids Differentially Downregulate Chemokines in Liver Sinusoidal Endothelial Cells: Insights into Non-Alcoholic Fatty Liver Disease.
    McMahan RH; Porsche CE; Edwards MG; Rosen HR
    PLoS One; 2016; 11(12):e0168301. PubMed ID: 27930747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCAT1 overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder.
    Chang IW; Wu WJ; Wang YH; Wu TF; Liang PI; He HL; Yeh BW; Li CF
    Histopathology; 2016 Mar; 68(4):520-32. PubMed ID: 26173071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of branched-chain amino acid aminotransferase (Bcat1/Eca39) in apoptosis.
    Eden A; Benvenisty N
    FEBS Lett; 1999 Aug; 457(2):255-61. PubMed ID: 10471790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction: Association of inflammatory genes in obstructive sleep apnea and non alcoholic fatty liver disease in Asian Indians residing in north India.
    Bhatt SP; Guleria R; Vikram NK; Vivekanandhan S; Singh Y; Gupta AK
    PLoS One; 2018; 13(8):e0203182. PubMed ID: 30138466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction: High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men.
    Lee J; Yoon K; Ryu S; Chang Y; Kim HR
    PLoS One; 2018; 13(10):e0206834. PubMed ID: 30372496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: Family history and obesity in youth, their effect on acylcarnitine/aminoacids metabolomics and non-alcoholic fatty liver disease (NAFLD). Structural equation modeling approach.
    Romero-Ibarguengoitia ME; Vadillo-Ortega F; Caballero AE; Ibarra-González I; Herrera-Rosas A; Serratos-Canales MF; León-Hernández M; González-Chávez A; Mummidi S; Duggirala R; López-Alvarenga JC
    PLoS One; 2018; 13(5):e0198379. PubMed ID: 29795696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defect of branched-chain amino acid metabolism promotes the development of Alzheimer's disease by targeting the mTOR signaling.
    Li H; Ye D; Xie W; Hua F; Yang Y; Wu J; Gu A; Ren Y; Mao K
    Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29802157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction: The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice.
    Bae CR; Zhang H; Kwon YG
    PLoS One; 2021; 16(4):e0249747. PubMed ID: 33819305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction: Spontaneous Evolution in Bilirubin Levels Predicts Liver-Related Mortality in Patients with Alcoholic Hepatitis.
    Lee M; Kim W; Choi Y; Kim S; Kim D; Yu SJ; Lee JH; Kim HY; Jung YJ; Kim BG; Kim YJ; Yoon JH; Lee KL; Lee HS
    PLoS One; 2016; 11(11):e0167184. PubMed ID: 27861575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and Monkeys.
    Singh SB; Kang L; Nawrocki AR; Zhou D; Wu M; Previs S; Miller C; Liu H; Hines CD; Madeira M; Cao J; Herath K; Spears LD; Semenkovich CF; Wang L; Kelley DE; Li C; Guan HP
    PLoS One; 2017; 12(1):e0170721. PubMed ID: 28103304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids.
    Panosyan EH; Lasky JL; Lin HJ; Lai A; Hai Y; Guo X; Quinn M; Nelson SF; Cloughesy TF; Nghiemphu PL
    J Neurooncol; 2016 May; 128(1):57-66. PubMed ID: 26922345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction: Intestinal short-chain fatty acid composition does not explain gut microbiota-mediated effects on malaria severity.
    Chakravarty S; Mandal RK; Duff ML; Yuan F; Zhang X; Schmidt NW
    PLoS One; 2019; 14(6):e0218250. PubMed ID: 31170258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial.
    Navarro VJ; Belle SH; D'Amato M; Afdhal N; Brunt EM; Fried MW; Rajender Reddy K; Wahed AS; Harrison S;
    PLoS One; 2019; 14(10):e0223915. PubMed ID: 31600349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction: Modeling the natural history of fatty liver using lifestyle-related risk factors: Effects of body mass index (BMI) on the life-course of fatty liver.
    Aizawa M; Inagaki S; Moriyama M; Asano K; Kakehashi M
    PLoS One; 2019; 14(12):e0226059. PubMed ID: 31790502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction: Nonalcoholic fatty liver disease is a risk factor for large-for-gestational-age birthweight.
    Lee SM; Kim BJ; Koo JN; Norwitz ER; Oh IH; Kim SM; Kim SY; Kim GM; Kwak SH; Kim W; Joo SK; Shin S; Vixay C; Park CW; Jun JK; Park JS
    PLoS One; 2019; 14(10):e0224845. PubMed ID: 31665185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.